The approval of ARCALYST™ (rilonacept) exemplifies Regeneron's commitment to discover, develop, and commercialize important medicines for patients
suffering from serious diseases.
Regeneron Pharmaceuticals, Inc. currently markets ARCALYST Injection for Subcutaneous Use for the treatment of a rare, inherited, inflammatory condition.
Highlights
For further information about ARCALYST, call 1-877-REGN-777 (1-877-734-6777)